Somatomedin-C (SM-C). Study in diabetic patients with and without retinopathy.
Acta Diabetol Lat
; 26(3): 217-24, 1989.
Article
em En
| MEDLINE
| ID: mdl-2694716
ABSTRACT
In the present study we evaluated somatomedin-C (Sm-C) plasma levels in diabetic patients, with and without retinopathy. One hundred and thirty four diabetic patients (65 type I and 69 type II) and 90 controls, strictly matched for age and sex, were enrolled in the study. Ophthalmoscopy and fluorescein angiography allowed to distinguish 49 patients without retinopathy, 45 patients with background retinopathy, and 40 with proliferative retinopathy. Growth hormone (GH) and Sm-C plasma levels were measured using a pool of 20-24 blood samples over 24h. Sm-C levels in type I (0.62 +/- 0.11 U/ml) and type II (0.56 +/- 0.09 U/ml) patients were significantly decreased (p less than 0.01) when compared to controls (0.89 +/- 0.30 U/ml). The mean daily secretion of GH was significantly (p less than 0.01) greater in diabetic patients (7.8 +/- 2.6 ng/ml) than in controls (4.1 +/- 1.5 ng/ml), but no correlation was found between Sm-C and GH (r = 0.15; p = n.s.). Our findings did not show any correlation between Sm-C plasma levels and either the existence of retinopathy, regardless of the degree of microvascular damage, or duration of the disease, or degree of metabolic control, as evaluated by HbA1c.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Somatomedinas
/
Fator de Crescimento Insulin-Like I
/
Diabetes Mellitus Tipo 1
/
Diabetes Mellitus Tipo 2
/
Retinopatia Diabética
Idioma:
En
Ano de publicação:
1989
Tipo de documento:
Article